Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Arcus Biosciences, Inc.NYSE: RCUS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns negative
Q2 FY2026 net income was -$91M, compared with $0 a year earlier. Trailing-twelve-month net income was -$460M. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Net income amounted to 142.9% of revenue in FY2025, up 33.2 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$381.08M (+8.0%) for the fiscal year ending Dec 2026, a slowdown from the +24.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$91M-28.9% QoQ
- Last fiscal yearDec 2025
- -$353M+24.7% YoY
- LTMJun 2026
- -$460M+54.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | -15.9% | — |
| 1 year | +24.7% | +8.0% | -16.8 pp |
| 3-year CAGR | +9.8% | +6.6% | -3.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (353M) USD
- Year-over-year change
- -24.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (353M) | -24.7% |
| FY2024 | 2024-12-31 | (283M) | +7.8% |
| FY2023 | 2023-12-31 | (307M) | -15.0% |
| FY2022 | 2022-12-31 | (267M) | -605.4% |
| FY2021 | 2021-12-31 | 52.83M | — |
Net Income vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 net income of $460M is the 3rd largest of the 9 companies compared; the peer median is $382.08M.
- Its year-over-year change of +54.4% is the 3rd highest of 9, against a peer median of +22.6%.
- Net income amounts to 393.2% of revenue for RCUS, versus a peer median of 558.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.11B | +218.3% | -5.5% | 607.8% | |
| LTM Jun 2026 | $511.45M | +6.8% | +16.3% | 14191.2% | |
| LTM Jun 2026 | $460M | +54.4% | +9.8% | 393.2% | |
| LTM Mar 2026 | $422.6M | -163.5% | +21.2% | 639.8% | |
| LTM Jun 2026 | $386.97M | +12.5% | +38.2% | 544.1% | |
| LTM Jun 2026 | $377.18M | +32.8% | +32.9% | — | |
| LTM Mar 2026 | $290.5M | +50.7% | +55.3% | 558.2% | |
| LTM Jun 2026 | $85.43M | -78.6% | -34.8% | 54.7% | |
| LTM Jun 2026 | $16.82M | +111.9% | +18.9% | 3.7% | |
| Peer median (excluding RCUS) | $382.08M | +22.6% | +20.0% | 558.2% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 52.83M | (267M) | (307M) | (283M) | (353M) |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 55M | 65M | 73M | 76M | 60M |
| Change in Working Capital | (375.62M) | 623M | (71M) | 22M | (194M) |
| Accounts Receivables | (17.05M) | 704M | 15M | 28M | 9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.77M) | 8M | (1M) | 3M | 24M |
| Other Working Capital | (353.8M) | (89M) | (85M) | (9M) | (227M) |
| Other Non-Cash Items | 7.62M | 11M | (9M) | 5M | (5M) |
| Operating Cash Flow | (256.17M) | 438M | (306M) | (170M) | (482M) |
| Capital Expenditures | (26.08M) | (6M) | (24M) | (6M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (718.87M) | (1.24B) | (788M) | (1.04B) | (1.08B) |
| Sales of Investments | 741.08M | 837M | 1.01B | 965M | 1.14B |
| Other Investing Activities | 0 | (3M) | 0 | 0 | 0 |
| Investing Cash Flow | (3.87M) | (413M) | 194M | (84M) | 66M |
| Debt Repayment | 5M | 0 | 0 | 47M | 49M |
| Common Stock Issued | 232.35M | 23M | 25M | 228M | 439M |
| Common Stock Repurchased | (6K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 10M | 8M | 2M | 0 |
| Financing Cash Flow | 237.34M | 33M | 33M | 277M | 488M |
| Effect of Forex Changes | (2.8M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | (25.5M) | 58M | (79M) | 23M | 72M |
| Free Cash Flow | (282.25M) | 432M | (330M) | (176M) | (484M) |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.